Cellectis S.A.
CLLS · NASDAQ
Market closed$2.63$-0.040000 (-1.50%)After hours $2.56 · -2.66%
Key statistics
Previous close$2.67
Open$2.70
Day high$2.70
Day low$2.62
52-week high$5.48
52-week low$1.77
Market cap264.10M
Volume7.89K
Average volume32.84K
P/E ratio-3.93
Forward P/E—
EPS-0.67
Dividend yield0.00%
Market context
Why it moved
CLLS shares drifted lower on light volume amid a lack of company-specific catalysts, reflecting broad selling pressure in the small-cap biotech space as investors rotated away from speculative names.
What is happening
Recent company-specific developments and publisher coverage.
MarketBeat · July 17, 2026Cellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of "Moderate Buy" from BrokeragesBarchart · July 7, 2026Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida TherapeuticsStock Titan · July 2, 2026Cellectis monthly capital update shows 100.7M shares, 105.6M votesStock Titan · June 25, 2026Cellectis shareholders back 29 motions, reject one at June 25 meetingGuruFocus · June 18, 2026Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares RiseGuruFocus · June 18, 2026Cellectis (CLLS) Achieves RMAT Designation for CAR-T TherapyInvesting.com · June 10, 2026Cellectis stock rises on FDA therapy designationInvesting.com · April 14, 2026Cellectis stock rating held at outperform on allogeneic platform Mt Newswire · June 11, 2026Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients Mt Newswire · June 9, 2026Cellectis Says US FDA Granted RMAT Designation to Lasme-cel to Treat r/r B-ALL Patients Benzinga · May 28, 2026Barclays Initiates Coverage On Cellectis with Overweight Rating, Announces Price Target of $9 Benzinga · May 12, 2026Cellectis To Present Phase 1 CAR-T Data For Lasme-cel And Eti-cel At EHA 2026, Highlighting Early Safety, Response Signals And Ongoing Pivotal Programs Benzinga · May 11, 2026Cellectis Q1 Adj. EPS $(0.16) Beats $(0.27) Estimate, Sales $7.548M Miss $12.267M Estimate Benzinga · April 27, 2026Cellectis Presents New Research On TALE-Based Epigenetic Editing Approach At ASGCT Annual Meeting Benzinga · April 14, 2026Citizens Reiterates Market Outperform on Cellectis, Maintains $8 Price Target Benzinga · December 16, 2025Allogene Arbitration Victory Pressures Cellectis Shares Tuesday